Mergers and Acquisitions Rewind: Bristol-Myers Squibb PURCHASES Amylin, Research In Motion Buyout RUMORS
Bristol-Myers Squibb Company (NYSE:BMY) should now finalize its $7 billion purchase of Amylin Pharmaceuticals, Inc. (NASDAQ:AMLN) following its gaining tenders for 85.55 percent of the latter’s shares. Through the terms, AztraZenica Group plc (NYSE:AZN) will now pay $3.4 billion to the buyer, as part of a collaboration arrangement for developing and commercializing Amylin’s products.
Shares of Research In Motion Limited (NASDAQ:RIMM) spike, but there is no news story that might have caused the movements. However, merger and acquisition chatter has been all over the firm recently as Tuesday morning Jefferies contended that Samsung might be interested and a columnist from The Street said much the same for Facebook.
A123 Systems, Inc. (NASDAQ:AONE) shares have been up and down Wednesday as investors digest the details of its financing agreement with China’s Wanxiang Group which includes a bridge loan, convertible notes, and warrants. Tom Konrad at Forbes calculates that Wanxiang should be able to purchase an 80 percent investment in A123 at 55 cents per share, which is a bit over its late afternoon level of 40 cents.
Want news like this in real-time so you can get an edge? Click here for Wall St. Cheat Sheet Pro.